|
1. Biologie
|
|
|
|
|
3.4 Chimioprévention
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE backs routine use of Incyte’s leukaemia drug [PharmaTimes]
|
|
|
|
|
|
The
independent appraisal committee has concluded that the drug can be
considered a clinical and cost effective use of NHS resources when used
to treat these rare forms of the disease, noting that it offers benefits
over other treatments such as Pfizer's Bosulif (bosutinib).
|
|
|
|
|
|
|
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia [NICE]
|
|
|
|
|
|
The
appraisal committee reviewed the data available on the clinical and
cost effectiveness of ponatinib, having considered evidence on the
nature of chronic myeloid leukaemia (CML) and acute lymphoblastic
leukaemia (ALL) and the value placed on the benefits of ponatinib by
people with the condition, those who represent them, and clinical
experts. It also took into account the effective use of NHS resources.
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
'Right to Try' is a sham [The Hill]
|
|
|
|
|
|
A
pediatric oncologist responded, “If you had seen, as I have, children
with cancer being given experimental drugs who were 'tortured' by the
drugs as they died, you would not be so cavalier.” Those words changed
my perspective.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|